Corcept Therapeutics Ownership | Who Owns Corcept Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Corcept Therapeutics Ownership Summary

Corcept Therapeutics is owned by 21.57% institutional investors, 11.54% insiders, and 66.89% retail investors. Blackrock is the largest institutional shareholder, holding 16.09% of CORT shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.31% of its assets in Corcept Therapeutics shares.

CORT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Corcept Therapeutics	21.57%	11.54%	66.89%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	16.54M	16.09%	$537.36M
Blackrock funding, inc. /de	12.15M	11.70%	$489.82M
Vanguard group	9.49M	9.17%	$330.42M
Ingalls & snyder	7.61M	7.33%	$306.71M
Renaissance	5.68M	5.47%	$229.07M
Parallel advisors	3.98M	3.83%	$160.33M
State street	3.20M	3.08%	$129.03M
Fmr	3.19M	3.07%	$128.60M
Geode capital management	2.71M	2.61%	$109.40M
First trust advisors lp	2.17M	2.09%	$87.61M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Tanaka capital management	111.21K	16.64%	$9.24M
Checkpoint capital	392.33K	10.92%	$32.61M
Ingalls & snyder	7.61M	10.86%	$306.71M
Sio capital management	674.76K	3.90%	$27.20M
Propel bio management	147.83K	3.80%	$6.02M
Tang capital management	1.50M	3.07%	$60.47M
Bioimpact capital	985.70K	3.07%	$39.73M
Parallel advisors	3.98M	2.88%	$160.33M
Fas wealth partners	308.32K	1.74%	$25.62M
Boxer capital management	250.00K	1.32%	$10.08M

Top Buyers

Holder	Shares	% Assets	Change
First trust advisors lp	2.17M	0.06%	1.48M
Tang capital management	1.50M	3.07%	1.34M
D. e. shaw	1.18M	0.03%	1.01M
Bioimpact capital	985.70K	3.07%	985.70K
Ubs group	1.36M	0.01%	948.82K

Top Sellers

Holder	Shares	% Assets	Change
Novo	-	-	-2.41M
Td asset management	-	-	-994.84K
Ikarian capital	-	-	-994.50K
Epoch investment partners	-	-	-816.65K
Jpmorgan chase	200.95K	0.00%	-633.50K

New Positions

Holder	Shares	% Assets	Change	Value
Bioimpact capital	985.70K	3.07%	985.70K	$39.73M
Norges bank	695.77K	0.00%	695.77K	$24.21M
Sio capital management	674.76K	3.90%	674.76K	$27.20M
Vanguard fiduciary trust	590.31K	0.01%	590.31K	$23.80M
Soleus capital management	285.53K	0.47%	285.53K	$11.51M

Sold Out

Holder	Change
Tfc financial management	-1.00
Tortoise investment management	-1.00
Turning point benefit group	-3.00
Horizon investments	-3.00
Cedar mountain advisors	-4.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	178	-57.31%	22,402,023	-70.75%	21	0.39%	71	-61.41%	72	-54.43%
Dec 31, 2025	281	-37.56%	56,456,655	-26.85%	54	0.99%	115	-47.25%	111	-24.49%
Sep 30, 2025	427	-0.93%	76,942,418	2.16%	73	1.41%	209	-5.86%	137	-9.87%
Jun 30, 2025	432	-3.79%	78,890,554	-3.87%	75	1.22%	221	-7.14%	154	10.79%
Mar 31, 2025	449	14.83%	82,236,144	-2.40%	78	1.19%	236	15.12%	140	15.70%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
iShares Core S&P Small-Cap ETF	5.71M	5.31%	1.22K
Vanguard Total Stock Mkt Idx Inv	2.88M	2.68%	24.55K
Vanguard US Total Market Shares ETF	2.83M	2.68%	213.93K
Vanguard Small Cap Index	2.08M	1.94%	-4.85K
iShares Russell 2000 ETF	2.03M	1.91%	-
First Trust NYSE Arca Biotech ETF	1.80M	1.67%	-8.37K
Fidelity Contrafund	1.19M	1.10%	-
Vanguard Small Cap Growth Index Inv	1.17M	1.09%	-668.00
Vanguard Institutional Extnd Mkt Idx Tr	1.06M	0.98%	9.86K
State Street SPDR Port S&P 600 Sm CpETF	855.64K	0.80%	298.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 02, 2026	Guyer William	Chief Development Officer	Sell	$1.41M
Jun 01, 2026	Maduck Sean	See Remarks	Sell	$278.10K
Jun 01, 2026	Maduck Sean	See Remarks	Sell	$1.48M
Jun 01, 2026	Mokari Atabak	Chief Financial Officer	Sell	$2.80M
Jun 01, 2026	BELANOFF JOSEPH K	Chief Executive Officer	Sell	$895.25K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	11
2026 Q1	2	5
2025 Q4	-	26
2025 Q3	-	31
2025 Q2	-	36

CORT Ownership FAQ

Who Owns Corcept Therapeutics?

Corcept Therapeutics shareholders are primarily institutional investors at 21.57%, followed by 11.54% insiders and 66.89% retail investors. The average institutional ownership in Corcept Therapeutics's industry, Biotech Stocks , is 35.75%, which Corcept Therapeutics falls below.

Who owns the most shares of Corcept Therapeutics?

Corcept Therapeutics’s largest shareholders are Blackrock (16.54M shares, 16.09%), Blackrock funding, inc. /de (12.15M shares, 11.70%), and Vanguard group (9.49M shares, 9.17%). Together, they hold 36.96% of Corcept Therapeutics’s total shares outstanding.

Does Blackrock own Corcept Therapeutics?

Yes, BlackRock owns 16.09% of Corcept Therapeutics, totaling 16.54M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 537.36M$. In the last quarter, BlackRock decreased its holdings by -287K shares, a -1.71% change.

Who is Corcept Therapeutics’s biggest shareholder by percentage of total assets invested?

Tanaka capital management is Corcept Therapeutics’s biggest shareholder by percentage of total assets invested, with 16.64% of its assets in 111.21K Corcept Therapeutics shares, valued at 9.24M$.

Who is the top mutual fund holder of Corcept Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Corcept Therapeutics shares, with 5.31% of its total shares outstanding invested in 5.71M Corcept Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools